ID   CDKL5_HUMAN             Reviewed;        1030 AA.
AC   O76039; G9B9X4; Q14198; Q5H985; Q8IYC7; Q9UJL6;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   10-MAY-2017, entry version 173.
DE   RecName: Full=Cyclin-dependent kinase-like 5;
DE            EC=2.7.11.22;
DE   AltName: Full=Serine/threonine-protein kinase 9;
GN   Name=CDKL5; Synonyms=STK9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9721213; DOI=10.1006/geno.1998.5391;
RA   Montini E., Andolfi G., Caruso A., Buchner G., Walpole S.M.,
RA   Mariani M., Consalez G.G., Trump D., Ballabio A., Franco B.;
RT   "Identification and characterization of a novel serine-threonine
RT   kinase gene from the Xp22 region.";
RL   Genomics 51:427-433(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN EIEE2,
RP   CHROMOSOMAL TRANSLOCATION, AND VARIANT PRO-791.
RX   PubMed=12736870; DOI=10.1086/375538;
RA   Kalscheuer V.M., Tao J., Donnelly A., Hollway G., Schwinger E.,
RA   Kuebart S., Menzel C., Hoeltzenbein M., Tommerup N., Eyre H.,
RA   Harbord M., Haan E., Sutherland G.R., Ropers H.-H., Gecz J.;
RT   "Disruption of the serine/threonine kinase 9 gene causes severe X-
RT   linked infantile spasms and mental retardation.";
RL   Am. J. Hum. Genet. 72:1401-1411(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=21748340; DOI=10.1007/s00439-011-1058-x;
RA   Williamson S.L., Giudici L., Kilstrup-Nielsen C., Gold W., Pelka G.J.,
RA   Tam P.P., Grimm A., Prodi D., Landsberger N., Christodoulou J.;
RT   "A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an
RT   alternative C-terminus and is the predominant transcript in brain.";
RL   Hum. Genet. 131:187-200(2012).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 339-789.
RX   PubMed=8864140;
RA   Krause S.W., Rehli M., Kreutz M., Schwarzfischer L., Paulauskis J.D.,
RA   Andreesen J.D.;
RT   "Differential screening leads to novel genetic markers of monocyte to
RT   macrophage maturation.";
RL   J. Leukoc. Biol. 60:540-545(1996).
RN   [6]
RP   INVOLVEMENT IN EIEE2.
RX   PubMed=15492925; DOI=10.1086/426462;
RA   Weaving L.S., Christodoulou J., Williamson S.L., Friend K.L.,
RA   McKenzie O.L.D., Archer H., Evans J., Clarke A., Pelka G.J.,
RA   Tam P.P.L., Watson C., Lahooti H., Ellaway C.J., Bennetts B.,
RA   Leonard H., Gecz J.;
RT   "Mutations of CDKL5 cause a severe neurodevelopmental disorder with
RT   infantile spasms and mental retardation.";
RL   Am. J. Hum. Genet. 75:1079-1093(2004).
RN   [7]
RP   INTERACTION WITH MECP2, FUNCTION, AUTOPHOSPHORYLATION, AND INVOLVEMENT
RP   IN EIEE2.
RX   PubMed=15917271; DOI=10.1093/hmg/ddi198;
RA   Mari F., Azimonti S., Bertani I., Bolognese F., Colombo E.,
RA   Caselli R., Scala E., Longo I., Grosso S., Pescucci C., Ariani F.,
RA   Hayek G., Balestri P., Bergo A., Badaracco G., Zappella M.,
RA   Broccoli V., Renieri A., Kilstrup-Nielsen C., Landsberger N.;
RT   "CDKL5 belongs to the same molecular pathway of MeCP2 and it is
RT   responsible for the early-onset seizure variant of Rett syndrome.";
RL   Hum. Mol. Genet. 14:1935-1946(2005).
RN   [8]
RP   FUNCTION, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANTS EIEE2 PHE-152 AND SER-175.
RX   PubMed=16935860; DOI=10.1074/jbc.M606325200;
RA   Bertani I., Rusconi L., Bolognese F., Forlani G., Conca B.,
RA   De Monte L., Badaracco G., Landsberger N., Kilstrup-Nielsen C.;
RT   "Functional consequences of mutations in CDKL5, an X-linked gene
RT   involved in infantile spasms and mental retardation.";
RL   J. Biol. Chem. 281:32048-32056(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407 AND SER-761, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407 AND SER-720, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-479 AND SER-720, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   VARIANTS EIEE2 PHE-152 AND SER-175, AND VARIANT PRO-791.
RX   PubMed=15499549; DOI=10.1086/426460;
RA   Tao J., Van Esch H., Hagedorn-Greiwe M., Hoffmann K., Moser B.,
RA   Raynaud M., Sperner J., Fryns J.-P., Schwinger E., Gecz J.,
RA   Ropers H.-H., Kalscheuer V.M.;
RT   "Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9)
RT   gene are associated with severe neurodevelopmental retardation.";
RL   Am. J. Hum. Genet. 75:1149-1154(2004).
RN   [15]
RP   INVOLVEMENT IN EIEE2.
RX   PubMed=15689447; DOI=10.1136/jmg.2004.026237;
RA   Scala E., Ariani F., Mari F., Caselli R., Pescucci C., Longo I.,
RA   Meloni I., Giachino D., Bruttini M., Hayek G., Zappella M.,
RA   Renieri A.;
RT   "CDKL5/STK9 is mutated in Rett syndrome variant with infantile
RT   spasms.";
RL   J. Med. Genet. 42:103-107(2005).
RN   [16]
RP   VARIANT EIEE2 ASN-72, AND VARIANT CYS-444.
RX   PubMed=16015284; DOI=10.1038/sj.ejhg.5201451;
RA   Evans J.C., Archer H.L., Colley J.P., Ravn K., Nielsen J.B., Kerr A.,
RA   Williams E., Christodoulou J., Gecz J., Jardine P.E., Wright M.J.,
RA   Pilz D.T., Lazarou L., Cooper D.N., Sampson J.R., Butler R.,
RA   Whatley S.D., Clarke A.J.;
RT   "Early onset seizures and Rett-like features associated with mutations
RT   in CDKL5.";
RL   Eur. J. Hum. Genet. 13:1113-1120(2005).
RN   [17]
RP   VARIANTS EIEE2 LEU-180 AND ALA-793.
RX   PubMed=16611748; DOI=10.1136/jmg.2006.041467;
RA   Archer H.L., Evans J., Edwards S., Colley J., Newbury-Ecob R.,
RA   O'Callaghan F., Huyton M., O'Regan M., Tolmie J., Sampson J.,
RA   Clarke A., Osborne J.;
RT   "CDKL5 mutations cause infantile spasms, early onset seizures, and
RT   severe mental retardation in female patients.";
RL   J. Med. Genet. 43:729-734(2006).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-368.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-374; GLN-574; ALA-734; PRO-791 AND
RP   GLY-1023.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [20]
RP   VARIANTS EIEE2 VAL-40; PRO-220 AND MET-718.
RX   PubMed=18790821; DOI=10.1093/brain/awn197;
RA   Bahi-Buisson N., Nectoux J., Rosas-Vargas H., Milh M., Boddaert N.,
RA   Girard B., Cances C., Ville D., Afenjar A., Rio M., Heron D.,
RA   N'guyen Morel M.A., Arzimanoglou A., Philippe C., Jonveaux P.,
RA   Chelly J., Bienvenu T.;
RT   "Key clinical features to identify girls with CDKL5 mutations.";
RL   Brain 131:2647-2661(2008).
RN   [21]
RP   VARIANTS EIEE2 VAL-40 AND PRO-220, AND CHARACTERIZATION OF VARIANTS
RP   EIEE2 VAL-40 AND PRO-220.
RX   PubMed=17993579; DOI=10.1136/jmg.2007.053504;
RA   Rosas-Vargas H., Bahi-Buisson N., Philippe C., Nectoux J., Girard B.,
RA   N'Guyen Morel M.A., Gitiaux C., Lazaro L., Odent S., Jonveaux P.,
RA   Chelly J., Bienvenu T.;
RT   "Impairment of CDKL5 nuclear localisation as a cause for severe
RT   infantile encephalopathy.";
RL   J. Med. Genet. 45:172-178(2008).
RN   [22]
RP   VARIANTS EIEE2 PRO-178; ILE-288 AND TYR-291.
RX   PubMed=18809835; DOI=10.1212/01.wnl.0000326592.37105.88;
RA   Elia M., Falco M., Ferri R., Spalletta A., Bottitta M., Calabrese G.,
RA   Carotenuto M., Musumeci S.A., Lo Giudice M., Fichera M.;
RT   "CDKL5 mutations in boys with severe encephalopathy and early-onset
RT   intractable epilepsy.";
RL   Neurology 71:997-999(2008).
RN   [23]
RP   VARIANT EIEE2 THR-399.
RX   PubMed=19253388; DOI=10.1002/ajmg.a.32711;
RA   Sprovieri T., Conforti F.L., Fiumara A., Mazzei R., Ungaro C.,
RA   Citrigno L., Muglia M., Arena A., Quattrone A.;
RT   "A novel mutation in the X-linked cyclin-dependent kinase-like 5
RT   (CDKL5) gene associated with a severe Rett phenotype.";
RL   Am. J. Med. Genet. A 149:722-725(2009).
RN   [24]
RP   VARIANTS EIEE2 THR-72 AND ARG-127, AND VARIANTS PRO-791 AND CYS-923.
RX   PubMed=19241098; DOI=10.1007/s10048-009-0177-1;
RA   Russo S., Marchi M., Cogliati F., Bonati M.T., Pintaudi M.,
RA   Veneselli E., Saletti V., Balestrini M., Ben-Zeev B., Larizza L.;
RT   "Novel mutations in the CDKL5 gene, predicted effects and associated
RT   phenotypes.";
RL   Neurogenetics 10:241-250(2009).
RN   [25]
RP   VARIANT EIEE2 GLN-178.
RX   PubMed=24564546; DOI=10.1186/1471-2350-15-24;
RA   Zhao Y., Zhang X., Bao X., Zhang Q., Zhang J., Cao G., Zhang J.,
RA   Li J., Wei L., Pan H., Wu X.;
RT   "Clinical features and gene mutational spectrum of CDKL5-related
RT   diseases in a cohort of Chinese patients.";
RL   BMC Med. Genet. 15:24-24(2014).
RN   [26]
RP   VARIANTS EIEE2 LEU-196 AND ARG-994.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D.,
RA   Bigoni S., Barba C., Mari F., Montomoli M., Pisano T., Rosati A.,
RA   Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: Mediates phosphorylation of MECP2.
CC       {ECO:0000269|PubMed:15917271, ECO:0000269|PubMed:16935860}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with MECP2. {ECO:0000269|PubMed:15917271}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16935860}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O76039-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O76039-2; Sequence=VSP_044082;
CC         Note=Predominant transcript in brain.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, lung, kidney, prostate,
CC       ovary, placenta, pancreas and testis.
CC   -!- PTM: Autophosphorylated.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CDKL5 are found in
CC       patients manifesting early-onset seizures and spams and
CC       psychomotor impairment. Translocation t(X;6)(p22.3;q14);
CC       translocation t(X;7)(p22.3;p15).
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 2 (EIEE2)
CC       [MIM:300672]: A severe form of epilepsy characterized by seizures
CC       or spasms beginning in infancy. Patients with epileptic
CC       encephalopathy early infantile type 2 manifest features resembling
CC       Rett syndrome such as microcephaly, lack of speech development,
CC       stereotypic hand movements. However, EIEE2 and Rett syndrome are
CC       considered two distinct entities. {ECO:0000269|PubMed:12736870,
CC       ECO:0000269|PubMed:15492925, ECO:0000269|PubMed:15499549,
CC       ECO:0000269|PubMed:15689447, ECO:0000269|PubMed:15917271,
CC       ECO:0000269|PubMed:16015284, ECO:0000269|PubMed:16611748,
CC       ECO:0000269|PubMed:16935860, ECO:0000269|PubMed:17993579,
CC       ECO:0000269|PubMed:18790821, ECO:0000269|PubMed:18809835,
CC       ECO:0000269|PubMed:19241098, ECO:0000269|PubMed:19253388,
CC       ECO:0000269|PubMed:24564546, ECO:0000269|PubMed:27864847}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-10 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA61445.1; Type=Frameshift; Positions=415; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y15057; CAA75342.1; -; mRNA.
DR   EMBL; AY217744; AAO64440.1; -; mRNA.
DR   EMBL; HQ171445; ADN38258.1; -; mRNA.
DR   EMBL; Z92542; CAI42485.1; -; Genomic_DNA.
DR   EMBL; AL109798; CAI42485.1; JOINED; Genomic_DNA.
DR   EMBL; AL109798; CAI41159.1; -; Genomic_DNA.
DR   EMBL; Z92542; CAI41159.1; JOINED; Genomic_DNA.
DR   EMBL; X89059; CAA61445.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS14186.1; -. [O76039-1]
DR   CCDS; CCDS83458.1; -. [O76039-2]
DR   PIR; S58296; S58296.
DR   RefSeq; NP_001032420.1; NM_001037343.1. [O76039-1]
DR   RefSeq; NP_001310218.1; NM_001323289.1. [O76039-2]
DR   RefSeq; NP_003150.1; NM_003159.2. [O76039-1]
DR   UniGene; Hs.659851; -.
DR   UniGene; Hs.696079; -.
DR   PDB; 4BGQ; X-ray; 2.00 A; A=1-303.
DR   PDBsum; 4BGQ; -.
DR   ProteinModelPortal; O76039; -.
DR   SMR; O76039; -.
DR   BioGrid; 112668; 16.
DR   IntAct; O76039; 7.
DR   MINT; MINT-7241055; -.
DR   STRING; 9606.ENSP00000369325; -.
DR   BindingDB; O76039; -.
DR   ChEMBL; CHEMBL1163112; -.
DR   iPTMnet; O76039; -.
DR   PhosphoSitePlus; O76039; -.
DR   BioMuta; CDKL5; -.
DR   EPD; O76039; -.
DR   MaxQB; O76039; -.
DR   PaxDb; O76039; -.
DR   PeptideAtlas; O76039; -.
DR   PRIDE; O76039; -.
DR   DNASU; 6792; -.
DR   Ensembl; ENST00000379989; ENSP00000369325; ENSG00000008086. [O76039-1]
DR   Ensembl; ENST00000379996; ENSP00000369332; ENSG00000008086. [O76039-1]
DR   Ensembl; ENST00000623535; ENSP00000485244; ENSG00000008086. [O76039-2]
DR   GeneID; 6792; -.
DR   KEGG; hsa:6792; -.
DR   UCSC; uc004cym.4; human. [O76039-1]
DR   CTD; 6792; -.
DR   DisGeNET; 6792; -.
DR   GeneCards; CDKL5; -.
DR   HGNC; HGNC:11411; CDKL5.
DR   HPA; CAB011577; -.
DR   HPA; HPA002847; -.
DR   MalaCards; CDKL5; -.
DR   MIM; 300203; gene.
DR   MIM; 300672; phenotype.
DR   neXtProt; NX_O76039; -.
DR   OpenTargets; ENSG00000008086; -.
DR   PharmGKB; PA36218; -.
DR   eggNOG; KOG0593; Eukaryota.
DR   eggNOG; ENOG410XNSW; LUCA.
DR   GeneTree; ENSGT00830000128262; -.
DR   HOGENOM; HOG000049181; -.
DR   HOVERGEN; HBG050863; -.
DR   InParanoid; O76039; -.
DR   KO; K08824; -.
DR   OMA; KSEVGLY; -.
DR   OrthoDB; EOG091G01A9; -.
DR   PhylomeDB; O76039; -.
DR   TreeFam; TF101032; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   SignaLink; O76039; -.
DR   SIGNOR; O76039; -.
DR   ChiTaRS; CDKL5; human.
DR   GeneWiki; CDKL5; -.
DR   GenomeRNAi; 6792; -.
DR   PRO; PR:O76039; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000008086; -.
DR   CleanEx; HS_CDKL5; -.
DR   ExpressionAtlas; O76039; baseline and differential.
DR   Genevisible; O76039; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0032839; C:dendrite cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0044294; C:dendritic growth cone; ISS:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:HGNC.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0048365; F:Rac GTPase binding; ISS:BHF-UCL.
DR   GO; GO:0001764; P:neuron migration; ISS:BHF-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; ISS:BHF-UCL.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:HGNC.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0050773; P:regulation of dendrite development; ISS:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   Epilepsy; Kinase; Mental retardation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   1030       Cyclin-dependent kinase-like 5.
FT                                /FTId=PRO_0000085826.
FT   DOMAIN       13    297       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      19     27       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    784    789       Poly-Lys.
FT   ACT_SITE    135    135       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      42     42       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     407    407       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     479    479       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     720    720       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     761    761       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ     905   1030       DGGCDGRRQRHHSGPQDRRFMLRTTEQQGEYFCCGDPKKPH
FT                                TPCVPNRALHRPISSPAPYPVLQVRGTSMCPTLQVRGTDAF
FT                                SCPTQQSGFSFFVRHVMREALIHRAQVNQAALLTYHENAAL
FT                                TGK -> GQMDPGWHVSSVTRSATEGPSYSEQLGAKSGPNG
FT                                HPYNRTNRSRMPNLNDLKETAL (in isoform 2).
FT                                {ECO:0000303|PubMed:21748340}.
FT                                /FTId=VSP_044082.
FT   VARIANT      40     40       A -> V (in EIEE2; causes mislocalization
FT                                of the protein in the cytoplasm;
FT                                dbSNP:rs122460159).
FT                                {ECO:0000269|PubMed:17993579,
FT                                ECO:0000269|PubMed:18790821}.
FT                                /FTId=VAR_058022.
FT   VARIANT      72     72       I -> N (in EIEE2; dbSNP:rs62641235).
FT                                {ECO:0000269|PubMed:16015284}.
FT                                /FTId=VAR_058023.
FT   VARIANT      72     72       I -> T (in EIEE2; dbSNP:rs62641235).
FT                                {ECO:0000269|PubMed:19241098}.
FT                                /FTId=VAR_058024.
FT   VARIANT     127    127       H -> R (in EIEE2; dbSNP:rs267608468).
FT                                {ECO:0000269|PubMed:19241098}.
FT                                /FTId=VAR_058025.
FT   VARIANT     152    152       C -> F (in EIEE2; affect activity; causes
FT                                mislocalization of the protein in the
FT                                cytoplasm; dbSNP:rs122460157).
FT                                {ECO:0000269|PubMed:15499549,
FT                                ECO:0000269|PubMed:16935860}.
FT                                /FTId=VAR_023560.
FT   VARIANT     175    175       R -> S (in EIEE2; affect activity; does
FT                                not affect the cellular distribution of
FT                                the protein; dbSNP:rs61749700).
FT                                {ECO:0000269|PubMed:15499549,
FT                                ECO:0000269|PubMed:16935860}.
FT                                /FTId=VAR_023561.
FT   VARIANT     178    178       R -> P (in EIEE2; dbSNP:rs267606715).
FT                                {ECO:0000269|PubMed:18809835}.
FT                                /FTId=VAR_058026.
FT   VARIANT     178    178       R -> Q (in EIEE2; dbSNP:rs267606715).
FT                                {ECO:0000269|PubMed:24564546}.
FT                                /FTId=VAR_071103.
FT   VARIANT     180    180       P -> L (in EIEE2; dbSNP:rs61749704).
FT                                {ECO:0000269|PubMed:16611748}.
FT                                /FTId=VAR_037635.
FT   VARIANT     196    196       S -> L (in EIEE2).
FT                                {ECO:0000269|PubMed:27864847}.
FT                                /FTId=VAR_078219.
FT   VARIANT     220    220       L -> P (in EIEE2; causes mislocalization
FT                                of the protein in the cytoplasm;
FT                                dbSNP:rs267608511).
FT                                {ECO:0000269|PubMed:17993579,
FT                                ECO:0000269|PubMed:18790821}.
FT                                /FTId=VAR_058027.
FT   VARIANT     288    288       T -> I (in EIEE2; dbSNP:rs267606713).
FT                                {ECO:0000269|PubMed:18809835}.
FT                                /FTId=VAR_058028.
FT   VARIANT     291    291       C -> Y (in EIEE2; dbSNP:rs267606714).
FT                                {ECO:0000269|PubMed:18809835}.
FT                                /FTId=VAR_058029.
FT   VARIANT     368    368       N -> H (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036578.
FT   VARIANT     374    374       A -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041997.
FT   VARIANT     399    399       N -> T (in EIEE2; dbSNP:rs267608611).
FT                                {ECO:0000269|PubMed:19253388}.
FT                                /FTId=VAR_058030.
FT   VARIANT     444    444       R -> C (in dbSNP:rs61753977).
FT                                {ECO:0000269|PubMed:16015284}.
FT                                /FTId=VAR_058031.
FT   VARIANT     574    574       P -> Q (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041998.
FT   VARIANT     718    718       V -> M (in EIEE2; dbSNP:rs267608653).
FT                                {ECO:0000269|PubMed:18790821}.
FT                                /FTId=VAR_058032.
FT   VARIANT     734    734       T -> A (in dbSNP:rs55803460).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041999.
FT   VARIANT     791    791       Q -> P (in dbSNP:rs35478150).
FT                                {ECO:0000269|PubMed:12736870,
FT                                ECO:0000269|PubMed:15499549,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:19241098}.
FT                                /FTId=VAR_023562.
FT   VARIANT     793    793       V -> A (in EIEE2; unknown pathological
FT                                significance; dbSNP:rs62643617).
FT                                {ECO:0000269|PubMed:16611748}.
FT                                /FTId=VAR_037636.
FT   VARIANT     923    923       R -> C (in dbSNP:rs267608664).
FT                                {ECO:0000269|PubMed:19241098}.
FT                                /FTId=VAR_058033.
FT   VARIANT     994    994       G -> R (in EIEE2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:27864847}.
FT                                /FTId=VAR_078220.
FT   VARIANT     999    999       V -> M (in dbSNP:rs35693326).
FT                                /FTId=VAR_037637.
FT   VARIANT    1023   1023       E -> G (in dbSNP:rs34166184).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042000.
FT   CONFLICT    339    340       HR -> GT (in Ref. 5; CAA61445).
FT                                {ECO:0000305}.
FT   CONFLICT    541    541       L -> W (in Ref. 5; CAA61445).
FT                                {ECO:0000305}.
FT   CONFLICT    731    764       Missing (in Ref. 5; CAA61445).
FT                                {ECO:0000305}.
FT   TURN         10     12       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       13     24       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       26     32       {ECO:0000244|PDB:4BGQ}.
FT   TURN         33     35       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       38     43       {ECO:0000244|PDB:4BGQ}.
FT   HELIX        55     66       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       75     81       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       84     90       {ECO:0000244|PDB:4BGQ}.
FT   STRAND       93     95       {ECO:0000244|PDB:4BGQ}.
FT   HELIX        96    102       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       109    128       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       138    140       {ECO:0000244|PDB:4BGQ}.
FT   STRAND      141    143       {ECO:0000244|PDB:4BGQ}.
FT   STRAND      149    151       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       180    183       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       191    206       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       216    227       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       232    240       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       242    244       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       258    262       {ECO:0000244|PDB:4BGQ}.
FT   TURN        263    265       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       268    277       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       282    284       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       288    292       {ECO:0000244|PDB:4BGQ}.
FT   HELIX       295    298       {ECO:0000244|PDB:4BGQ}.
SQ   SEQUENCE   1030 AA;  115538 MW;  8A1C9C438610EF08 CRC64;
     MKIPNIGNVM NKFEILGVVG EGAYGVVLKC RHKETHEIVA IKKFKDSEEN EEVKETTLRE
     LKMLRTLKQE NIVELKEAFR RRGKLYLVFE YVEKNMLELL EEMPNGVPPE KVKSYIYQLI
     KAIHWCHKND IVHRDIKPEN LLISHNDVLK LCDFGFARNL SEGNNANYTE YVATRWYRSP
     ELLLGAPYGK SVDMWSVGCI LGELSDGQPL FPGESEIDQL FTIQKVLGPL PSEQMKLFYS
     NPRFHGLRFP AVNHPQSLER RYLGILNSVL LDLMKNLLKL DPADRYLTEQ CLNHPTFQTQ
     RLLDRSPSRS AKRKPYHVES STLSNRNQAG KSTALQSHHR SNSKDIQNLS VGLPRADEGL
     PANESFLNGN LAGASLSPLH TKTYQASSQP GSTSKDLTNN NIPHLLSPKE AKSKTEFDFN
     IDPKPSEGPG TKYLKSNSRS QQNRHSFMES SQSKAGTLQP NEKQSRHSYI DTIPQSSRSP
     SYRTKAKSHG ALSDSKSVSN LSEARAQIAE PSTSRYFPSS CLDLNSPTSP TPTRHSDTRT
     LLSPSGRNNR NEGTLDSRRT TTRHSKTMEE LKLPEHMDSS HSHSLSAPHE SFSYGLGYTS
     PFSSQQRPHR HSMYVTRDKV RAKGLDGSLS IGQGMAARAN SLQLLSPQPG EQLPPEMTVA
     RSSVKETSRE GTSSFHTRQK SEGGVYHDPH SDDGTAPKEN RHLYNDPVPR RVGSFYRVPS
     PRPDNSFHEN NVSTRVSSLP SESSSGTNHS KRQPAFDPWK SPENISHSEQ LKEKEKQGFF
     RSMKKKKKKS QTVPNSDSPD LLTLQKSIHS ASTPSSRPKE WRPEKISDLQ TQSQPLKSLR
     KLLHLSSASN HPASSDPRFQ PLTAQQTKNS FSEIRIHPLS QASGGSSNIR QEPAPKGRPA
     LQLPDGGCDG RRQRHHSGPQ DRRFMLRTTE QQGEYFCCGD PKKPHTPCVP NRALHRPISS
     PAPYPVLQVR GTSMCPTLQV RGTDAFSCPT QQSGFSFFVR HVMREALIHR AQVNQAALLT
     YHENAALTGK
//
